Best Available Therapy

DRUG11 trials

Sponsors

Pfizer, CTI BioPharma, Novartis Pharmaceuticals, Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.), Shionogi

Conditions

Abdominal InfectionAcute PyelonephritisBacteremiaBloodstream InfectionsBloodstream Infections (BSI)COVID-19Carbapenem-Resistant Enterobacteriaceae InfectionComplicated Intra-abdominal Infection

Phase 2

RCT Cefiderocol vs BAT for Treatment of Gram Negative BSI

CompletedNCT03869437

The University of QueenslandBloodstream Infections

Start: 2019-10-28End: 2024-01-29Updated: 2024-02-13

Convalescent Plasma Compared to the Best Available Therapy for the Treatment of SARS-CoV-2 Pneumonia

CompletedNCT04358783

Hospital Universitario Dr. Jose E. GonzalezCoronavirus Infection

Start: 2020-04-27End: 2021-05-01Updated: 2021-05-26

Study to Assess Efficacy and Safety of NS-018 Compared to BAT in Patients With Myelofibrosis

TerminatedNCT04854096

NS Pharma, Inc.Post-essential Thrombocythemia Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Primary Myelofibrosis

Start: 2023-01-31End: 2024-05-16Updated: 2025-05-23

Phase 3

Ceftazidime-Avibactam for the Treatment of Infections Due to Ceftazidime Resistant Pathogens

CompletedNCT01644643

PfizerComplicated Intra-abdominal Infection, Complicated Urinary Tract Infection

Start: 2013-01-31End: 2014-09-30Updated: 2017-09-29

Pacritinib Versus Best Available Therapy to Treat Myelofibrosis

TerminatedNCT01773187

CTI BioPharmaPost-essential Thrombocythemia Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Primary Myelofibrosis

Start: 2013-01-31End: 2016-04-30Updated: 2020-09-29

Ruxolitinib Efficacy and Safety in Patients With HU Resistant or Intolerant Polycythemia Vera vs Best Available Therapy.

CompletedNCT02038036

Novartis PharmaceuticalsPolycythemia Vera

Start: 2014-03-25End: 2020-04-07Updated: 2021-07-20

Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia

TerminatedNCT02055781

CTI BioPharmaPost-essential Thrombocythemia Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Primary Myelofibrosis

Start: 2014-02-28End: 2016-04-30Updated: 2021-11-18

Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults

CompletedNCT02168946

Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)Abdominal Infection, Acute Pyelonephritis, Bacteremia +3

Start: 2014-07-31End: 2017-07-21Updated: 2019-03-04

Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens

CompletedNCT02714595

ShionogiBloodstream Infections (BSI), Complicated Urinary Tract Infection (cUTI), Healthcare-associated Pneumonia (HCAP) +3

Start: 2016-09-07End: 2019-04-22Updated: 2021-01-12

Unknown Phase

Impact of Ceftazidime / Avibactam Treatment vs Better Available Therapy on Mortality of Patients With Infections Caused by Carbapenem-resistant Enterobacteria

CompletedNCT04167228

Maimónides Biomedical Research Institute of CórdobaCarbapenem-Resistant Enterobacteriaceae Infection

Start: 2019-10-01End: 2021-05-05Updated: 2021-07-20

Calcifediol in the Treatment of COVID 19

CompletedNCT05819918

Maimónides Biomedical Research Institute of CórdobaCOVID-19

Start: 2022-04-01End: 2023-04-17Updated: 2023-04-28

Related Papers

Pacritinib in patients with high-risk myelofibrosis: Outcomes from post-hoc analyses of two Phase 3 studies

Blood2025-11-03

Cefiderocol versus standard therapy for hospital-acquired and health-care-associated Gram-negative bacterial bloodstream infection (the GAME CHANGER trial): an open-label, parallel-group, randomised trial.

2025-10-061 citations

ALBACOVIDIOL Study: Effect of Calcifediol Treatment on Mortality in Patients Hospitalized for COVID-19: A Retrospective Analysis

Nutrients2025-06-10

Transfusion-related cost and time burden offsets in patients with myelofibrosis treated with pacritinib compared to best available therapy based on PERSIST-2 trial.

Journal of Clinical Oncology2025-05-28

Improvement in Serum Albumin As a Measure of Improved Metabolic Profile in Pacritinib-Treated Patients: A Retrospective Analysis of Patients Treated across Three Clinical Trials

Blood2024-11-05

Pacritinib Response Is Associated With Overall Survival in Myelofibrosis: <scp>PERSIST</scp>‐2 Landmark Analysis of Survival

European Journal Of Haematology2024-10-145 citations

Latent Class Analysis Reveals, in patient profiles, COVID-19-related better prognosis by calcifediol treatment than glucocorticoids.

2024-08-311 citations

Efficacy of pacritinib in patients with myelofibrosis who have both thrombocytopenia and anemia.

Journal of Clinical Oncology2024-06-011 citations

Impact of pacritinib on symptoms in with thrombocytopenia and myelofibrosis who require red blood cell transfusion.

Journal of Clinical Oncology2024-06-01

Efficacy and safety of ceftazidime/avibactam in patients with infections caused by β-lactamase-producing Gram-negative pathogens: a pooled analysis from the Phase 3 clinical trial programme

Journal of Antimicrobial Chemotherapy2023-09-1316 citations

Matching-adjusted indirect comparison of the pelabresib-ruxolitinib combination vs JAKi monotherapy in myelofibrosis

Blood Advances2023-08-027 citations

PB2232: A RANDOMIZED, CONTROLLED CLINICAL TRIAL (PHASE 2B) OF NS-018 VERSUS BEST AVAILABLE THERAPY IN SUBJECTS WITH PRIMARY OR SECONDARY MYELOFIBROSIS WITH SEVERE THROMBOCYTOPENIA

HemaSphere2023-08-01

Spleen volume reduction (SVR) predicts overall survival (OS) in myelofibrosis (MF) patients on pacritinib (PAC) but not best available therapy (BAT): PERSIST-2 landmark OS analysis.

Journal of Clinical Oncology2023-06-012 citations

Consistency of pacritinib for spleen and symptom reduction in patients with myelofibrosis regardless of cytopenias.

Journal of Clinical Oncology2023-06-01

Differential Impact of Thrombocytopenia and Anemia on Myelofibrosis (MF) Symptom Burden

Blood2022-11-15

Risk-adjusted safety analysis of pacritinib (PAC) in patients (pts) with myelofibrosis (MF).

Journal of Clinical Oncology2022-06-015 citations

P1059: COMPARATIVE EFFICACY OF FEDRATINIB AND PACRITINIB FOR THE TREATMENT OF MYELOFIBROSIS IN PATIENTS WITH LOW PLATELET COUNTS: A SIMULATED TREATMENT COMPARISON STUDY

HemaSphere2022-06-01

Ruxolitinib versus best available therapy in inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): 5-year follow up of a randomised, phase 3b study.

2022-05-1832 citations

Outcomes with Cefiderocol Treatment in Patients with Bacteraemia Enrolled into Prospective Phase 2 and Phase 3 Randomised Clinical Studies.

2022-02-2013 citations

Mechanisms of Reduced Susceptibility to Cefiderocol Among Isolates from the CREDIBLE-CR and APEKS-NP Clinical Trials

Microbial Drug Resistance2022-01-2566 citations

33 more papers not shown